Compare Organon & Co. Common Stock (OGN) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $44.72 (market cap $524.91M). The key difference: Organon & Co. Common Stock is far larger — about 6.9× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 52 Days on average.
| OGN | QCLN | |
|---|---|---|
Market Cap | $3.62B | $524.91M |
Volume | 2,892,999 | 261,814 |
Sector | Health | Sector/Thematic |
52-Week High | $13.81 | $68.47 |
52-Week Low | $5.70 | $41.10 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
QCLN trades at $47.24, showing minimal daily movement with a 0.25% gain. Technical indicators signal bearish momentum as the stock trades below key moving averages, though oversold RSI conditions suggest potential near-term support. Recent news highlights the ETF's sensitivity to political outcomes and global energy transitions, with geopolitical tensions driving renewed interest in clean energy investments.
The fund's performance remains heavily dependent on policy developments and energy market dynamics. While global renewable energy acceleration provides long-term tailwinds, near-term volatility persists due to political uncertainty and technical weakness. Investors face balanced risk-reward with policy catalysts potentially offsetting current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
